Ciltacabtagene autoleucel clinical trials
Also written JNJ-68284528.
How each study uses ciltacabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ciltacabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Feb 2022 · Carvykti · BLA 125746 (FDA, Purple Book)
- European Union
- 25 May 2022 · Carvykti · EMEA/H/C/005095 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Janssen Research & Development, LLC (5) · Dana-Farber Cancer Institute (1) · Janssen Scientific Affairs, LLC (1) · Washington University School of Medicine (1) · Medical College of Wisconsin (1) · Nanjing Legend Biotech Co. (1)
Often tested with
Tested in the same studies.
Bortezomib (2) · Dexamethasone (2) · Daratumumab (2) · Talquetamab (2) · Cyclophosphamide (2) · Pomalidomide (1) · Lenalidomide (1) · Fludarabine phosphate (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test ciltacabtagene autoleucel.
- Feb 2027A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaPhase 2 · Janssen Research & Development, LLC
- Jun 2027Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionPhase 1 · Washington University School of Medicine
- Jul 2027Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaPhase 1 · Medical College of Wisconsin
Studies
Open first, then newest update. How each study uses ciltacabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingPhase 4Janssen Research & Development, LLCNCT05201781Written as Cilta-celHow we know
- Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionRecruitingPhase 1Washington University School of MedicineNCT06623630Written as Ciltacabtagene AutoleucelHow we know
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1Medical College of WisconsinNCT07093554Written as Ciltacabtagene AutoleucelHow we know
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04181827Written as Cilta-celHow we know
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06577025Written as Cilta-celHow we know
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT04133636Written as JNJ-68284528How we know
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT05767359Written as Ciltacabtagene AutoleucelHow we know
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedPhase 2Nanjing Legend Biotech Co.NCT03758417Written as LCAR-B38M CAR-T CellHow we know
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple MyelomaCompletedPhase 1/2Janssen Research & Development, LLCNCT03548207Written as JNJ-68284528How we know
- A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedPhase 2Janssen Scientific Affairs, LLCNCT05347485Written as Cilta-celHow we know
Given beside what is tested · 5 — ciltacabtagene autoleucel is usual care or a partner of the new treatment
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingPhase 2Janssen Research & Development, LLCNCT07149857Written as Cilta-celHow we know
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 2Mayo ClinicNCT06940297Written as Ciltacabtagene AutoleucelHow we know
- A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06550895Written as Cilta-celHow we know
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04923893Written as Cilta-celHow we know
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3Stichting European Myeloma NetworkNCT05257083Written as Cilta-celHow we know
Codes
What other systems call ciltacabtagene autoleucel · ClinicalTrials.gg INT014205
- UNII (FDA) 0L1F17908QCILTACABTAGENE AUTOLEUCELOne source FDA
- RxNorm 2594775One source FDA
- NCI Thesaurus C148498Ciltacabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0L1F17908Q | CILTACABTAGENE AUTOLEUCEL | One source FDA |
| RxNorm | 2594775 | — | One source FDA |
| NCI Thesaurus | C148498 | Ciltacabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.